Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
Ben Rothwell, Christopher Kiff, Caroline S. Ling, Thor‐Henrik Brodtkorb
Journal
- ISSN / E-ISSN
- — / —
- DOI
- 10.1007/s41669-020-00245-4 ↗
- Volume · Issue · Pages
- 5 · 2 · 251-260
- Publisher
- Springer Nature Switzerland AG
- Article URL
- https://doi.org/10.1007/s41669-020-00245-4 ↗
- Article details
- Unverified
Publication date (each date has its type and source)
17 Dec 2020
OpenAlex publication date · source: OpenAlex
| Type | Date | Source |
|---|---|---|
| OpenAlex publication date | 17 Dec 2020 | OpenAlex |
Keywords (as given): nivolumab; docetaxel; non-small cell lung cancer; cost-effectiveness; lung squamous cell carcinoma; non-squamous non-small cell lung cancer; previously treated advanced NSCLC; Cancer Drugs Fund; conditional reimbursement; quality-adjusted life years; incremental cost-effectiveness ratio; PD-L1 expression; partitioned survival model
HEC Status at Publication Not the journal's current status
HEC Status at PublicationNot conclusive
Historical status could not be conclusively determined.
- HEC status cannot be determined for this date: no HEC list is recorded as in effect on it.
Best available information, not a definitive status: HEC status cannot be determined for this date: no HEC list is recorded as in effect on it.
- Journal
- PharmacoEconomics - Open
- Publication date used
- 17 Dec 2020 (OpenAlex publication date)
- Applicable HEC period
- None recorded for this date
- Category
- —
- Recognition status
- Unknown (NO_PERIOD_FOR_DATE)
- Source
- —
- Verification status
- Not available
This is an automatically generated summary based on the information available on the publication date. Terms & conditions apply.